Global Finance News
07 Nov 2026, 11:26
Eli Lilly and Hims & Hers Partner to Expand Access to Zepbound and Foundayo
Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) announced an agreement to make Lilly’s FDA-approved obesity medicines Zepbound and Foundayo available through the Hims & Hers platform.
Eligible patients will be able to complete a telehealth consultation, receive a prescription when appropriate and have the medicines shipped directly to their homes without leaving the platform. Self-pay pricing will start at $149 per month for Foundayo and $299 per month for Zepbound.
The partnership gives Lilly another direct channel to reach obesity patients through digital healthcare while allowing Hims & Hers to expand its weight-loss offering with branded, FDA-approved GLP-1 medicines.
Hims & Hers said it has never offered compounded copies of Lilly’s GLP-1 products and committed not to do so in the future. The companies also said prescribing decisions will remain with independent licensed providers.
The agreement could strengthen Lilly’s reach in the rapidly growing obesity market while giving Hims & Hers a more competitive position in telehealth weight management through access to two of Lilly’s major obesity products.
Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) announced an agreement to make Lilly’s FDA-approved obesity medicines Zepbound and Foundayo available through the Hims & Hers platform.
Eligible patients will be able to complete a telehealth consultation, receive a prescription when appropriate and have the medicines shipped directly to their homes without leaving the platform. Self-pay pricing will start at $149 per month for Foundayo and $299 per month for Zepbound.
The partnership gives Lilly another direct channel to reach obesity patients through digital healthcare while allowing Hims & Hers to expand its weight-loss offering with branded, FDA-approved GLP-1 medicines.
Hims & Hers said it has never offered compounded copies of Lilly’s GLP-1 products and committed not to do so in the future. The companies also said prescribing decisions will remain with independent licensed providers.
The agreement could strengthen Lilly’s reach in the rapidly growing obesity market while giving Hims & Hers a more competitive position in telehealth weight management through access to two of Lilly’s major obesity products.
